公开(公告)号：US20240350479A1

公开(公告)日：2024-10-24

申请号：US18436555

申请日：2024-02-08

申请人： Purdue Pharma L.P.

发明人： Michele Hummel ,  Donald J. Kyle ,  Garth Whiteside

IPC分类号： A61K31/485 ,  A61K9/00 ,  A61K9/16 ,  A61K9/24 ,  A61K9/70 ,  A61K31/05 ,  A61K31/135 ,  A61K31/137 ,  A61K31/445 ,  A61K31/4468 ,  A61K31/451 ,  A61K31/4748 ,  A61K38/07

CPC分类号： A61K31/485 ,  A61K31/135 ,  A61K31/137 ,  A61K31/4468 ,  A61K31/451 ,  A61K31/4748 ,  A61K38/07 ,  A61K9/0019 ,  A61K9/167 ,  A61K9/209 ,  A61K9/7023 ,  A61K31/05 ,  A61K31/445

摘要： Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.

公开(公告)号：US12109221B2

公开(公告)日：2024-10-08

申请号：US17818841

申请日：2022-08-10

申请人： LEUKOS BIOTECH, S.L. ,  FUNDACIÓ INSTITUT DE RECERCA CONTRA LA LEUCÈMIA JOSEP CARRERAS

发明人： Ruth Muñoz Risueño ,  Mari Carmen Lara Castillo ,  Amaia Etxabe Alberdi

IPC分类号： A61K31/7068 ,  A61K31/485 ,  A61K31/55 ,  A61K31/706 ,  A61P35/02

CPC分类号： A61K31/7068 ,  A61K31/485 ,  A61K31/55 ,  A61K31/706 ,  A61P35/02

摘要： The invention relates to a combination comprising an antineoplastic agent, e.g. an antimetabolite antineoplastic agent and a type 1 serotonin receptor (HTR1) modulator, e.g. a HTR1 antagonist. In addition the invention relates to a pharmaceutical composition comprising a combination of the invention and a pharmaceutically acceptable excipient. The invention also relates to the combination and pharmaceutical composition according to the invention for use in medicine, particularly for use in the prevention and/or treatment of a hematological malignancy.

公开(公告)号：US12109209B2

公开(公告)日：2024-10-08

申请号：US18081842

申请日：2022-12-15

申请人： NIPPON CHEMIPHAR CO., LTD.

发明人： Hiroshi Nagase ,  Hideaki Fujii ,  Akiyoshi Saitoh ,  Eriko Nakata ,  Masaaki Hirose ,  Isao Ooi ,  Kohei Hayashida

IPC分类号： A61K31/485 ,  A61P25/04 ,  A61P25/06 ,  A61P25/22

CPC分类号： A61K31/485 ,  A61P25/04 ,  A61P25/06 ,  A61P25/22

摘要： A method for therapeutic treatment of pain-associated anxiety or depression in a mammalian subject in need thereof, that includes administering to the subject an effective amount of a pharmaceutical composition containing a morphinan derivative that exhibits an opioid δ receptor agonist activity.

公开(公告)号：US20240325380A1

公开(公告)日：2024-10-03

申请号：US18741475

申请日：2024-06-12

申请人： TMTRx, Inc.

发明人： Phillip R. Torralva

IPC分类号： A61K31/485 ,  A61K31/137 ,  A61K31/18 ,  A61K31/225 ,  A61K31/40 ,  A61K31/4166 ,  A61K31/4178 ,  A61K31/454 ,  A61K31/46 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/5517 ,  A61P25/36

CPC分类号： A61K31/485 ,  A61K31/137 ,  A61K31/18 ,  A61K31/225 ,  A61K31/40 ,  A61K31/4166 ,  A61K31/4178 ,  A61K31/454 ,  A61K31/46 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/5517 ,  A61P25/36

摘要： Compositions are provided including a Mu opioid receptor antagonist, and an α2-adrenergic receptor agonist; or an α1 adrenergic receptor antagonist, together with one or more of a mu (or opioid receptor subtype) antagonist or agonist, (2) a vasopressor, (3) an anticholinergic agent and/or cholinergic agents, (4) a combined alpha-1 adrenergic antagonist and anticholinergic, (5) a paralytic or muscle relaxant, (6) a respiratory accelerant, (7) a GABA complex antagonist, (8) an anti-seizure/membrane stabilizer agent, (9) an α1 adrenergic receptor agonist, and/or (10) an α2 adrenergic receptor agonist; and a pharmaceutically acceptable carrier. Also provided are methods of preventing or reversing effects in a subject (including muscle and chest wall rigidity, laryngospasm, WCS, and/or respiratory depression) arising from intentional or accidental opioid or opiate exposure.

公开(公告)号：US20240307384A1

公开(公告)日：2024-09-19

申请号：US18593518

申请日：2024-03-01

申请人： CalciMedica, Inc.

发明人： Gonul VELICELEBI ,  Kenneth STAUDERMAN ,  Michael DUNN ,  Jack ROOS

IPC分类号： A61K31/497 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/421 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/485 ,  A61K31/506 ,  A61K45/06 ,  A61P1/18 ,  C07D401/04 ,  C07D405/04 ,  C07D413/14 ,  C07D417/10 ,  C07D417/14 ,  C07D491/04

CPC分类号： A61K31/497 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/421 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/485 ,  A61K31/506 ,  A61K45/06 ,  A61P1/18 ,  C07D401/04 ,  C07D405/04 ,  C07D413/14 ,  C07D417/10 ,  C07D417/14 ,  C07D491/04 ,  Y02A50/30

摘要： Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.

公开(公告)号：US20240299320A1

公开(公告)日：2024-09-12

申请号：US18669417

申请日：2024-05-20

申请人： ANTECIP BIOVENTURES II LLC

发明人： Herriot Tabuteau

IPC分类号： A61K31/137 ,  A61K9/20 ,  A61K31/4525 ,  A61K31/485 ,  A61P25/24

CPC分类号： A61K31/137 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2086 ,  A61K31/4525 ,  A61K31/485 ,  A61P25/24

摘要： This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

公开(公告)号：US12083117B2

公开(公告)日：2024-09-10

申请号：US17498152

申请日：2021-10-11

申请人： The Procter & Gamble Company

发明人： Kelly Lee Martin Schmeichel ,  Jayant Eknath Khanolkar ,  Douglas William Gledhill ,  Susan Elaine Criss ,  Niranjan Ramji ,  Elaine Rose Costeines ,  Thomas Edward Huetter ,  Radhika R. Iyer ,  Daren K. Anness

IPC分类号： A61K31/485 ,  A61J1/05 ,  A61K9/00 ,  A61K9/08 ,  A61K31/137 ,  A61K31/167 ,  A61K31/473 ,  A61K31/495 ,  A61K31/519 ,  A61K31/522 ,  A61K31/55 ,  A61K31/616 ,  A61K45/06 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26

CPC分类号： A61K31/485 ,  A61J1/05 ,  A61K9/0095 ,  A61K9/08 ,  A61K31/137 ,  A61K31/167 ,  A61K31/473 ,  A61K31/495 ,  A61K31/519 ,  A61K31/522 ,  A61K31/55 ,  A61K31/616 ,  A61K45/06 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61K31/137 ,  A61K2300/00 ,  A61K31/473 ,  A61K2300/00 ,  A61K31/485 ,  A61K2300/00 ,  A61K31/495 ,  A61K2300/00 ,  A61K31/519 ,  A61K2300/00 ,  A61K31/522 ,  A61K2300/00 ,  A61K31/55 ,  A61K2300/00 ,  A61K31/616 ,  A61K2300/00

摘要： A stable liquid composition in a clear bottle wherein the composition comprises from about 0.001% to about 0.5% of phenylephrine hydrochloride, by weight of the stable liquid composition. The composition comprises less than about 0.1% of total aldehydes, by weight of the stable liquid composition, and has a pH from about 2 to about 6.5. The clear bottle comprises a material selected from polyethylene terephthalate (PET), glycol-modified polyethylene terephthalate (PETG), oriented polypropylene (OPP), polyvinylchloride (PVC), polyvinylidene chloride (PVDC), nylon, polyethylene terephthalate polyester (PETP), polyphene, or combinations thereof.

公开(公告)号：US20240285613A1

公开(公告)日：2024-08-29

申请号：US18573362

申请日：2022-06-23

申请人： LDN Pharma Limited

发明人： Wai Liu ,  Ian Thompson ,  Francis Hood

IPC分类号： A61K31/485 ,  A61K31/00 ,  A61K31/01 ,  A61K31/015 ,  A61K31/045 ,  A61K31/08 ,  A61K31/133 ,  A61K31/135 ,  A61K31/137 ,  A61K31/164 ,  A61K31/165 ,  A61K31/232 ,  A61K31/343 ,  A61K31/352 ,  A61K31/353 ,  A61K31/357 ,  A61K31/366 ,  A61K31/4045 ,  A61K31/42 ,  A61K31/454 ,  A61K31/48 ,  A61K31/575 ,  A61K31/593 ,  A61K31/675 ,  A61K31/7048 ,  A61K45/06

CPC分类号： A61K31/485 ,  A61K31/01 ,  A61K31/015 ,  A61K31/045 ,  A61K31/08 ,  A61K31/133 ,  A61K31/135 ,  A61K31/137 ,  A61K31/164 ,  A61K31/165 ,  A61K31/232 ,  A61K31/343 ,  A61K31/352 ,  A61K31/353 ,  A61K31/357 ,  A61K31/366 ,  A61K31/4045 ,  A61K31/42 ,  A61K31/454 ,  A61K31/48 ,  A61K31/575 ,  A61K31/593 ,  A61K31/658 ,  A61K31/675 ,  A61K31/7048 ,  A61K45/06

摘要： A pharmaceutical composition comprising naltrexone or a metabolite thereof or an analogue selected from the group consisting of methylnaltrexone, nalmefene and nalorphine, for use in the treatment of an autoimmune disease within a subject, wherein a therapeutically effective amount of the naltrexone or metabolite thereof or analogue of either is to be administered to the subject in a first treatment phase, wherein after the first treatment phase the subject is to be administered a therapeutically effective amount of a cannabinoid, flavonoid or terpene in a second treatment phase, and wherein an agonist of a 5-hydroxytryptamine (5-HT) receptor is to be administered to the subject either simultaneously, sequentially or separately with the naltrexone, the metabolite or analogue.

公开(公告)号：US20240277849A1

公开(公告)日：2024-08-22

申请号：US18169402

申请日：2023-02-15

申请人： AXSOME THERAPEUTICS, INC.

发明人： Herriot Tabuteau

IPC分类号： A61K47/54 ,  A61K9/20 ,  A61K9/24 ,  A61K31/485

CPC分类号： A61K47/542 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/209 ,  A61K31/485

摘要： This disclosure relates to pharmaceutical compositions comprising bupropion and cysteine, and pharmaceutical dosage forms comprising bupropion and cysteine. The disclosure also relates to molecular complexes of bupropion and cysteine. These compositions and dosage forms may have improved stability of bupropion.

公开(公告)号：US12048769B2

公开(公告)日：2024-07-30

申请号：US16938443

申请日：2020-07-24

申请人： Nalpropion Pharmaceuticals LLC

发明人： Anthony A McKinney ,  Gary D. Tollefson ,  Eckard Weber ,  Richard Soltero

IPC分类号： A61K9/24 ,  A61J1/03 ,  A61J7/04 ,  A61K31/135 ,  A61K31/137 ,  A61K31/138 ,  A61K31/35 ,  A61K31/42 ,  A61K31/423 ,  A61K31/485 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/7048 ,  A61K45/06 ,  B65D75/36

CPC分类号： A61K9/209 ,  A61J1/035 ,  A61J7/04 ,  A61K31/135 ,  A61K31/137 ,  A61K31/138 ,  A61K31/35 ,  A61K31/42 ,  A61K31/423 ,  A61K31/485 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/7048 ,  A61K45/06 ,  B65D75/36 ,  A61J7/0454 ,  A61K31/135 ,  A61K2300/00 ,  A61K31/137 ,  A61K2300/00 ,  A61K31/35 ,  A61K2300/00 ,  A61K31/42 ,  A61K2300/00 ,  A61K31/485 ,  A61K2300/00 ,  A61K31/551 ,  A61K2300/00

摘要： Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.